Jomarie Janco, MD
Gynecologic Oncology · la Jolla, CANPI 1851554315
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,578 of the $8,655 with a category attached, or 76.0%. AstraZeneca accounts for 91.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $5,818 and has fallen 90.6% since, to $548 in 2025.
Across 15 payments — averaging $576.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- Daiichi Sankyo Inc.$503
- GSK$98
- Astellas Pharma US Inc$88
- Exelixis Inc.$19
- Clovis Oncology, Inc.$19
- plus $36 from 2 others
Across 1 payment — averaging $40,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$40K
What the payments were for
- Consulting fees$6,57876%
- Grants$1,81921%
- Food & beverage$2593%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $7,894 |
| Daiichi Sankyo Inc. | 1 | $503 |
| GSK | 2 | $98 |
| Astellas Pharma US Inc | 3 | $88 |
| Exelixis Inc. | 1 | $19 |
| Clovis Oncology, Inc. | 1 | $19 |
| Viiv Healthcare Company | 1 | $18 |
| Seagen Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,655 in reported general payments places this provider in the 70th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 13 | $634 |
| Clobetasol Propionate | 13 | $171 |
| Gabapentin | 14 | $43 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in la Jolla
- Michael McHalela Jolla$68K
- Cheryl Saenzla Jolla$27K
- John ChanSan Francisco$2M
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
- Amer KaramStanford$168K
- Rebecca BrooksSacramento$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.